Prime Medicine prices $125M equity offering; net proceeds ~$120.2M for R&D

Prime Medicine, Inc.

Offering of 38M shares at $3.30/share; underwriters have 30-day option for 5.7M additional shares.
Estimated net proceeds of $120.2M after underwriting discounts and expenses.
Proceeds to fund Wilson's Disease and Alpha-1 Antitrypsin Deficiency programs; remainder for working capital.
Underwriting led by TD Securities and BMO Capital Markets; expected close August 1, 2025.
Cystic Fibrosis Foundation to purchase 1,818,181 shares without any underwriting discounts.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.